Strongbridge biopharma plc (SBBP)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Dec'14
ASSETS
Current assets:
Cash and cash equivalents

56,554

57,032

79,608

86,167

104,306

122,490

67,383

85,514

92,405

57,510

44,366

33,864

49,898

66,837

25,469

33,884

42,307

51,623

15,632

Marketable securities

6,293

21,072

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

2,690

2,289

3,362

6,343

3,916

1,626

2,542

2,376

2,016

1,584

979

616

-

-

-

-

-

-

-

Inventory

1,343

1,993

2,399

3,218

4,202

3,946

6,261

1,186

1,661

511

1,003

1,403

-

-

-

-

-

-

-

Prepaid expenses and other current assets

1,078

1,157

2,079

2,454

2,726

4,236

2,342

3,078

1,776

1,208

1,687

1,863

962

764

322

428

797

1,253

598

Total current assets

67,958

83,543

87,448

98,182

115,150

132,298

78,528

92,154

97,858

60,813

48,035

37,746

50,860

67,601

25,791

34,312

43,104

52,876

16,230

Property and equipment, net

270

291

280

291

292

294

297

315

12

15

17

20

22

25

27

30

32

35

21

Right of use asset, net

744

789

867

934

1,046

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax asset

-

-

-

-

-

-

-

-

-

-

-

-

-

1,599

-

-

-

-

-

Intangible asset, net

23,855

25,110

26,366

27,621

28,876

30,132

54,463

56,169

58,041

35,155

36,410

58,389

59,644

60,900

-

-

-

36,551

-

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31,323

31,323

36,551

-

5,228

Goodwill

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

7,256

2,200

Other assets

977

649

743

872

862

305

305

318

360

686

387

301

151

150

158

158

71

612

10

Total assets

101,060

117,638

122,960

135,156

153,482

170,285

140,849

156,212

163,527

103,925

92,105

103,712

117,933

137,531

64,555

73,079

87,014

97,330

23,689

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

5,285

3,331

1,961

1,469

7,494

1,184

3,227

2,411

2,168

1,247

1,422

1,200

1,880

1,089

1,012

1,966

1,284

2,792

887

Accrued and other current liabilities

18,513

20,962

18,648

17,035

14,854

16,065

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

19,985

11,856

8,837

11,232

8,793

6,958

7,877

14,868

3,228

2,869

4,809

2,685

1,422

Total current liabilities

23,798

24,293

20,609

18,504

22,348

17,249

23,212

14,267

11,005

12,479

10,215

8,158

9,757

15,957

4,240

4,835

6,093

5,477

2,309

Long-term debt

-

-

-

-

-

-

79,061

77,572

76,142

37,794

37,195

18,566

18,424

18,434

-

-

-

-

-

Warrant liability

3,547

4,127

5,434

8,636

17,333

15,513

22,721

31,991

51,008

41,308

39,284

41,237

26,018

11,090

-

-

-

-

-

Supply agreement liability, noncurrent

11,556

15,947

16,099

15,454

15,454

24,568

22,111

23,519

23,519

24,258

25,063

25,921

25,078

25,078

-

-

-

-

-

Other long-term liabilities

980

1,080

1,177

1,273

1,364

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based liability awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,183

Deferred tax liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

871

926

1,376

Total liabilities

39,881

45,447

43,319

43,867

56,499

57,330

147,105

147,349

161,674

115,839

111,757

93,882

79,277

70,559

4,240

4,835

6,964

6,403

4,868

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

Stockholders’ equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at March 31, 2020 and December 31, 2019

44

44

44

44

44

44

44

44

44

44

44

44

44

44

44

44

44

44

-

Ordinary shares, $0.01 par value, 600,000,000 shares authorized at March 31, 2020 and December 31, 2019; 54,247,501 and 54,205,852 shares issued and outstanding at March 31, 2020 and December 31, 2019

542

542

542

542

542

541

472

467

455

401

358

353

353

353

212

212

212

212

97

Additional paid-in capital

333,768

332,085

330,558

328,416

325,863

323,402

288,316

282,881

272,960

230,524

204,081

198,508

197,144

195,975

173,459

173,328

172,238

170,910

55,947

Accumulated deficit

-273,181

-260,483

-251,503

-237,713

-229,466

-211,032

-295,088

-274,529

-271,606

-242,883

-224,135

-189,075

-158,885

-129,400

-113,400

-105,799

-92,957

-80,803

-37,223

Accumulated other comprehensive income

6

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

459

513

564

-

Total stockholders’ equity

61,179

72,191

79,641

91,289

96,983

112,955

-6,256

8,863

1,853

-11,914

-19,652

9,830

38,656

66,972

60,315

68,244

80,050

90,927

18,821

Total liabilities and stockholders’ equity

101,060

117,638

122,960

135,156

153,482

170,285

140,849

156,212

163,527

103,925

92,105

103,712

117,933

137,531

64,555

73,079

87,014

97,330

23,689